Drugs News and Research

RSS

Xenogenics retains Emmes to assist with development, execution of its capital formation strategy

Xenogenics Corporation, a majority owned subsidiary of MultiCell Technologies, Inc., is pleased to announce it has retained the Emmes Group to assist with the development and execution of its capital formation strategy to help finance expanded human clinical trials of its Ideal BioStent.

24 Feb 2011

Researchers identify low-dose, two-drug cocktail that reduces noise-induced hearing loss in mice

Whether on a battlefield, in a factory or at a rock concert, noise-induced hearing loss is one of the most common hazards people face. Researchers at Washington University School of Medicine in St. Louis have identified a low-dose, two-drug cocktail that reduces hearing loss in mice when given before they are exposed to loud noise. The drugs, already FDA-approved for other conditions, also treat hearing loss after noise exposure.

23 Feb 2011

FDA grants Fast Track designation to Sunesis' vosaroxin for treatment of AML

Sunesis Pharmaceuticals, Inc. today announced that vosaroxin, the Company's lead drug candidate, has been granted Fast Track designation by the U.S. Food and Drug Administration for the potential treatment of relapsed or refractory acute myeloid leukemia in combination with cytarabine.

23 Feb 2011

Australia’s top scientist takes on top job

Today, the man who is known for one of Australia’s greatest medical achievements – the development of a cervical cancer vaccine – has been appointed as Chief Executive Officer of the Translational Research Institute (TRI) in Brisbane, Queensland.

23 Feb 2011

Diabetes technology granted patent in Australia

Living Cell Technologies Limited (ASX: LCT; OTCQX: LVCLY) a global company pioneering the development of a cell implant therapy to treat diabetes and neurodegenerative diseases, has been granted a patent by the Australian Patent Office for IMMUPEL(tm), LCT's industry-leading technology for encapsulating living cells prior to transplantation.

23 Feb 2011

Study results of NanoViricides anti-dengue drug candidates presented at NIH/NIAID sponsored conference

NanoViricides, Inc.announced today that Anil R. Diwan, PhD, President of the Company, gave a presentation on Friday, February 18th, that discussed the Company's anti-viral technology and more specifically, results from both in-vitro and in-vivo studies of its drug candidates against dengue virus infections that can potentially cause a fatal manifestation, viz. dengue hemorrhagic fever.

23 Feb 2011

USPTO issues patent to Synergy's SP-333 for treatment of IBD

Synergy Pharmaceuticals, Inc., a developer of new drugs to treat gastrointestinal disorders and diseases, announced today that on February 1, 2011 the U.S. Patent and Trademark Office issued U.S. Patent No. 7,879,802, covering Synergy's novel drug candidate SP-333 to treat inflammatory bowel disease.

23 Feb 2011

Pretreatment with FDA-approved drug allows successful pregnancies in radiation-exposed rhesus monkeys

A strategy developed by Massachusetts General Hospital (MGH) researchers to shield the ovaries of female mammals from the damaging effects of radiation and chemotherapy has passed an important milestone. A collaborative study with investigators from Oregon Health and Sciences University (OHSU), published online in the journal Fertility and Sterility, reports that brief preexposure of the ovaries to an FDA-approved agent called FTY720 preserved the fertility of female rhesus monkeys exposed to potentially lethal doses of radiation.

23 Feb 2011

Cannabis Science extract treatments help kill cancer cells

Cannabis Science, Inc. a pioneering U.S. biotech company developing pharmaceutical cannabis (marijuana derivative) products, is pleased to announce that numerous patients are reporting that Cannabis Science extract treatments are killing cancer cells.

23 Feb 2011

Antiepileptic drugs could make HIV drugs less effective

A Michigan State University researcher is looking to uncover the risks of treating seizures in HIV-positive patients, providing much-needed data on possible interactions between antiepileptic drugs and antiretroviral medicines that potentially could make HIV drugs less effective or the disease itself drug resistant.

23 Feb 2011

Roundup: Calif. hospital's unusual Medicare billing; Tenn. gastric bypass; Mass. Acos

Redding, where the Valley meets Cascade foothills, and Victorville, in the Mojave Desert, have little in common but an unusual statistic: In each city, a hospital has reported alarming rates of a Third World nutritional disorder among its Medicare patients. Kwashiorkor - a Ghanaian word for "weaning sickness" - is a severe protein deficiency that almost exclusively afflicts impoverished children in developing countries, especially during famines, experts say.

23 Feb 2011

Cerasome filled molecular-sized bubbles to target liver cancer cells

Nanotechnology may open a new door on the treatment of liver cancer, according to a team of Penn State College of Medicine researchers. They used molecular-sized bubbles filled with chemotherapy drugs to prevent cell growth and initiate cell death in test tubes and mice.

23 Feb 2011

UCI study details benefits of physical activity, diet, relationships, fun and spirituality

Getting more exercise, spending time outdoors and helping others are among the activities that can be as effective as drugs or counseling in treating an array of mental illnesses, including depression and anxiety, according to a UC Irvine study.

23 Feb 2011

Federal anti-drug campaign appears to reduce marijuana use among teenagers

The federal anti-drug campaign "Above the Influence" appears to have effectively reduced marijuana use by teenagers, new research shows.

23 Feb 2011

Researchers to explore genomes of childhood cancers

In a project supported by Genome BC, a Vancouver pediatric pathologist at the BC Cancer Agency/University of British Columbia is leading the team that will explore the genomes of four of the most challenging childhood cancers known.

23 Feb 2011

$Prolonged use of osteoporosis drugs may increase risk of unusual fractures in women$

Prolonged use of osteoporosis drugs may increase risk of unusual fractures in women

Women who take commonly prescribed drugs for osteoporosis known as bisphosphonates for five years or more may be at higher risk of certain kinds of fractures of their thigh bone, a new study has found.

23 Feb 2011

TransPharma completes ViaDor-GLP1 agonist Phase 1b trial for treatment of type II diabetes

TransPharma Medical Ltd., a specialty pharmaceutical company focused on the development and commercialization of drug products utilizing a proprietary active transdermal drug delivery technology, announced today the successful completion of a Phase 1b trial of ViaDor-GLP1 agonist, which is being developed for the treatment of diabetes mellitus type II.

22 Feb 2011

KemPharm commences KP201 Phase 1 trial for pain

KemPharm, Inc. today announced that it has commenced a Phase 1 clinical trial in healthy volunteers with KP201, its novel abuse deterrent prodrug of hydrocodone for pain. KP201 is a new chemical entity and is the most advanced opioid-based lead candidate in KemPharm's emerging pipeline.

22 Feb 2011

Mutated cancer pathway studies identify therapeutic targets for congenital heart disease

Cross-disciplinary teams of scientists studying genetic pathways that are mutated in many forms of cancer, but which also cause certain forms of congenital heart disease - including hypertrophic cardiomyopathy, a thickening of the heart muscle that is the leading cause of sudden death in children and young adults -, have introduced these mutations into mice and successfully treated HCM in the lab.

22 Feb 2011

Tropical seaweed's antifungal chemical cues may have promising antimalarial properties for humans

A group of chemical compounds used by a species of tropical seaweed to ward off fungus attacks may have promising antimalarial properties for humans. The compounds are part of a unique chemical signaling system that seaweeds use to battle enemies - and that may provide a wealth of potential new pharmaceutical compounds.

22 Feb 2011

Drugs News and Research

Xenogenics retains Emmes to assist with development, execution of its capital formation strategy

Researchers identify low-dose, two-drug cocktail that reduces noise-induced hearing loss in mice

FDA grants Fast Track designation to Sunesis' vosaroxin for treatment of AML

Australia’s top scientist takes on top job

Diabetes technology granted patent in Australia

Study results of NanoViricides anti-dengue drug candidates presented at NIH/NIAID sponsored conference

USPTO issues patent to Synergy's SP-333 for treatment of IBD

Pretreatment with FDA-approved drug allows successful pregnancies in radiation-exposed rhesus monkeys

Cannabis Science extract treatments help kill cancer cells

Antiepileptic drugs could make HIV drugs less effective

Roundup: Calif. hospital's unusual Medicare billing; Tenn. gastric bypass; Mass. Acos

Cerasome filled molecular-sized bubbles to target liver cancer cells

UCI study details benefits of physical activity, diet, relationships, fun and spirituality

Federal anti-drug campaign appears to reduce marijuana use among teenagers

Researchers to explore genomes of childhood cancers

Prolonged use of osteoporosis drugs may increase risk of unusual fractures in women

TransPharma completes ViaDor-GLP1 agonist Phase 1b trial for treatment of type II diabetes

KemPharm commences KP201 Phase 1 trial for pain

Mutated cancer pathway studies identify therapeutic targets for congenital heart disease

Tropical seaweed's antifungal chemical cues may have promising antimalarial properties for humans

Drug Discovery - Second Edition eBook

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News